Oxford BioMedica PLC
LSE:OXB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oxford BioMedica PLC
Common Shares Outstanding
Oxford BioMedica PLC
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Common Shares Outstanding
£120.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Common Shares Outstanding
$69.4m
|
CAGR 3-Years
32%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Common Shares Outstanding
£50.7m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Common Shares Outstanding
$96.1m
|
CAGR 3-Years
31%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Common Shares Outstanding
£66.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Niox Group PLC
LSE:NIOX
|
Common Shares Outstanding
£417.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
Oxford BioMedica PLC
Glance View
Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The company is headquartered in Oxford, Oxfordshire. The firm and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The firm's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The firm has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
See Also
What is Oxford BioMedica PLC's Common Shares Outstanding?
Common Shares Outstanding
120.8m
GBP
Based on the financial report for Dec 31, 2025, Oxford BioMedica PLC's Common Shares Outstanding amounts to 120.8m GBP.
What is Oxford BioMedica PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
9%
Over the last year, the Common Shares Outstanding growth was 14%. The average annual Common Shares Outstanding growth rates for Oxford BioMedica PLC have been 8% over the past three years , 8% over the past five years , and 9% over the past ten years .
